Chemo plus immunotherapy and anti-angiogenic drug for TNBC before surgery
Part of Cancer, Skin clinical trials.
This trial tests whether adding sintilimab (an immunotherapy) and bevacizumab (a drug that blocks blood supply to tumors) to standard chemotherapy before surgery can improve outcomes for women with stage II or III triple-negative breast cancer. It may help your immune system fight the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman between 18 and 70 years old.
- Your cancer must be stage II or III triple-negative breast cancer (ER negative, PR negative, and HER2 negative).
- Your tumor must show PD-L1 expression (a protein that can make immunotherapy more effective).
- You must have good overall health (ECOG score 0 or 1) and normal organ function.
- You must not have had prior cancer treatment or radiation for any other cancer (except certain cured cancers).
- You must agree to use effective birth control during and for 6 months after treatment if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether adding immunotherapy to chemotherapy before surgery helps people with triple-negative breast cancer. It compares different treatment approaches to see which works better.
This trial tests whether giving chemotherapy plus the immunotherapy drug toripalimab before surgery can improve outcomes for women with early-stage triple-negative breast cancer that tests positive for PD-L1.
This trial tests whether adding an immunotherapy drug called toripalimab to standard chemotherapy, before surgery, can improve treatment for early triple-negative breast cancer. It compares two chemotherapy approaches—one with anthracyclines and one without—to see which works better when combined with toripalimab.
This study tests whether adding an immune therapy (a PD-1 antibody) plus a blood-vessel–blocking treatment to standard chemo improves outcomes for people with surgically treated triple-negative breast cancer. Everyone gets chemotherapy, but some will also get the added drugs to try to reduce cancer coming back.
This trial studies a new drug called QL1706 (an immunotherapy that helps your immune system fight cancer) combined with standard chemotherapy before surgery. The goal is to see if this combination can shrink or eliminate the tumor more effectively in early-stage triple-negative breast cancer, potentially improving your long-term outcome.
This trial tests whether adding the drug ivonescimab to standard chemotherapy before surgery can improve outcomes for people with triple-negative breast cancer. The treatment is given before surgery to shrink the tumor and make surgery more effective.
Hear when a new TNBC - Triple-Negative Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.